HAEHaemonetics Corporation
$118.73+135% 1Y
$118.73
$47.6752 weeks$119.59
HAE in its own filings
Nothing in HAE's filing record raises a hard flag: no restatement, late filing, bankruptcy or delisting notice, and no auditor change next to one. That is the common case, not a distinction.
442
Events found in the filings · across 1,898 filings · the record starts in 1996
- Hard flags
- none
Hard flags
- Most recent filing
- Oct 8, 2026
Most recent filing · Form 8-K
- Record starts
- Jun 7, 1996
Record starts · the earliest filing Ryufin holds for this name
Details›
- Next results filingsame week as a year ago
- expected around Nov 5, 2026
- Material impairmenthistorical
- 2019-05-14
- SEC comment-letter activity27 occurrences
- 2017-02-02
SEC EDGAR submissions index and 8-K item codes; 4.02 and 1.03 items are confirmed against the filing text.
What the company said
The company's own words from its current reports to the SEC, newest first
- Aug 6, 2026Olga Guyette, Vice President-Investor Relations & Treasury.Earnings release · press release
- Jul 28, 2026On July 24, 2026, the Board of Directors of Haemonetics Corporation (the “Company”) elected Martin Madaus as a director of the Company, effective immediately.Director or officer change · Form 8-K
- Jun 5, 2026Olga Guyette, Vice President - Investor Relations & Treasury.Regulation FD disclosure · press release
- May 7, 2026Olga Guyette, Vice President-Investor Relations & Treasury.Earnings release · press release
- May 1, 2026On April 27, 2026, Charles J. Dockendorff informed Haemonetics Corporation (the “Company”) that he will not stand for re-election at the Company’s 2026 Annual Meeting of Shareholders (the “2026 Annual Meeting”)Director or officer change · Form 8-K
- Feb 5, 2026Olga Guyette, Vice President-Investor Relations & Treasury.Earnings release · press release
- Jan 9, 2026On January 9, 2026, Haemonetics Corporation (the “Company”) announced its acquisition of Vivasure Medical Limited (“Vivasure”), a Galway, Ireland-based company pioneering next-generation technology for percutaneous vessel closure.Other event · Form 8-K
- Nov 6, 2025Olga Guyette, Vice President-Investor Relations & Treasury.Earnings release · press release
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
opening the record…